Feeling tired, foggy, or simply not as sharp as you used to be? You're not alone—and that's precisely why NAD supplements have been making waves across the wellness world. From science-backed ...

It’s the most popular supplement on the market. But why do we need vitamin D—and why is the advice on how to get it so contradictory? Sunlight is all our bodies need to make vitamin D—a ...

Having to swallow a huge pill every day is the worst part of taking your daily vitamins. Not only can it make taking supplements unappealing, but also just plain tiring. Meet the experts ...

These days, the supplement aisle is growing by the minute, and that’s especially the case when it comes to sports and athletic performance supps. There’s protein powder, creatine, amino acids ...

The supplement industry has convinced millions of people that collagen drinks are the fountain of youth in powder form. But they conveniently left out one crucial detail that makes the difference ...

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno ...

Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely ...

Whether you need a fiber supplement depends on your health needs, your diet, and your symptoms. You might benefit from a fiber supplement if you are experiencing frequent gastrointestinal (GI) issues, ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all ...

As cases of drug-induced liver injury (DILI) are on the rise, experts are warning of the hidden dangers associated with some common medications and supplements. Statistics show that DILI ...

Merck paid $588 million to join the race the day after BioNTech disclosed the Biotheus takeover. Pfizer upped the ante last month by paying 3SBio $1.25 billion upfront for a PD-1xVEGF bispecific ...